NL-OMON34409已完成2 期
In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS). Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resistance and adipose tissue inflammation related to the metabolic syndrome - In vivo induction of HO in MetS.
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •At least 18 and not older than 70 years of age on the day of the first dosing.
- •Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- •Metabolic syndrome defined by at least three out of five criteria:
- •Elevated waist circumference (women >= 88, men >= 102 cm).
- •Elevated triglycerides or drug treatment (>= 1.7 mmol/L).
- •Reduced HDL-cholesterol or drug treatment (women < 1.3 mmol/L, men < 1.0 mmol/L).
- •Elevated blood pressure (systolic >= 130 mm Hg and/or diastolic >= 85 mm Hg)
- •Elevated fasting glucose (>= 6.1 mmol/L)
排除标准
- •History of smoking within the past year.
- •History of or current abuse of drugs, alcohol or solvents.
- •Known diabetes mellitus
- •Repeated systolic blood pressure >= 180 mm Hg in all subjects, >= 160 mm Hg in women >= 65 yrs old and >= 140 mm Hg in men >= 65 yrs old
- •Fasting plasma glucose > 7.0 mmol/L or HbA1c > 6.2%
- •Pregnancy or breast feeding (contraception for at least 3 months before inclusion is required for fertile women)
- •Current use of antihypertensive, cardiac or other vasoactive medication
- •Current use of acetylsalicylic acid and/or statin
- •Use of antioxidant vitamin supplements
- •Clinical evidence of cardiac or pulmonary disease
- •Laboratory evidence of renal or hepatic abnormalities, defined as results exceeding twice the upper limit of normal range.
- •Unconjugated hyperbilirubinemia (total bilirubin level > 10 µmol/L and a normal direct bilirubin level) suggesting the Gilbert Syndrome.
研究者
相似试验
进行中(未招募)
1 期
In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS).Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resistance and adipose tissue inflammation related to the metabolic syndrome - In vivo induction of HO in MetS.Subjects suffer from the metabolic syndrome. Effects of study medication on insulin resistance and vascular function will be studied respectively.MedDRA version: 12.1Level: LLTClassification code 10022489Term: Insulin resistanceMedDRA version: 12.1Level: LLTClassification code 10052066Term: Metabolic syndromeMedDRA version: 12.1Level: LLTClassification code 10048554Term: Endothelial dysfunctionEUCTR2010-020875-22-NLRUNMC16
招募中
不适用
The effects of heme arginate treatment on insulin resistance and vascular dysfunction related to obesity.Metabolic syndrome, insulin resistance and endothelial dysfunction.NL-OMON29539Radboud University Nijmegen Medical Centre16
进行中(未招募)
1 期
Induction of Heme Oxygenase-1: a therapeutic approach to reduce hepatic ischaemia-reperfusion injury in liver surgery - HOLS studyEUCTR2008-005955-40-GBniversity of Edinburgh42
已完成
不适用
Heme Oxygenase-1 in Liver Surgeryiver surgery/pharmacological preconditioningSurgeryLiver surgeryISRCTN94278797niversity of Edinburgh (UK)42
已完成
不适用
Relationship between activity in heme oxygenase-1 (HO-1) and risk factors for cardiovascular diseases in patients with obstructive sleep apnea (OSA)Obstructive sleep apnea syndromeJPRN-UMIN000006924Kyoto University Graduate School of Medicine80
